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ABSTRACT 
Objective: The SENTRY antimicrobial surveillance program was 
established to monitor the occurrence and antimicrobial sus- 
ceptibility of bacterial pathogens via an international network of 
sentinel hospitals. 
Material and Methods: Microorganisms were forwarded to the 
reference laboratory for testing against various antimicrobial 
agents using broth microdilution. Twenty European hospitals 
referred 286 Streptococcus pneumoniae, 309 Haemophilus 
influenzae, and 167 Moraxella catarrhalis isolates during the 
first IO months of the study, starting in April 1997. 
Results: Seven percent of the S. pneumoniae isolates were 
highly resistant to penicillin, and 21% showed intermediate 
resistance. The highly resistant pneumococcal isolates came 
from Coimbra, Barcelona, Athens, and London, whereas the 
intermediate penicillin-resistant isolates were received from all 
participating countries. The incidence of intermediate penicillin- 
resistant pneumococci was lowest in Lausanne, Freiburg and 
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Duesseldorf, London, and Utrecht and highest in southern 
European countries. Fifty-five percent of the penicillin-resistant 
S. pneumoniae were also resistant to erythromycin, and 35% 
to clindamycin. Sparfloxacin, trovafloxacin, levofloxacin, and 
vancomycin were fully active against pneumococcal isolates. 
Haemophilus influenzae isolates were generally highly suscep- 
tible to most of the antibiotics tested, and 92% of the M. 
catarrhak isolates were resistant to penicillin. Susceptibility to 
cephalosporins, ciprofloxacin, levofloxacin, and rifampicin was 
100%. 
Conclusion: Penicillin may no longer be the first-choice drug for 
empirical treatment of pneumococcal infections. The newer 
fluoroquinolones may play a role in the empirical treatment of 
community-acquired pneumonia. 
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Community-acquired respiratory tract infections are a 
major worldwide cause of morbidity and mortality. 
Chronic bronchitis affects more than 1 million people in 
the United Kingdom and more than 7 million in the 
United StateslJ Bacterial infections are responsible for 
approximately half of the acute exacerbations of this con- 
dition.3 The incidence levels for community-acquired 
pneumonia are 3.6/1000 per year and 3.3/1000 per year 
for the United Kingdom and United States, respectively.4,5 
Severe community-acquired pneumonia is associated with 
high morbidity and mortality.“~’ Treatment of these con- 
ditions is usually empirical, with penicillins normally 
being prescribed as the first-choice antibiotics for treat- 
ment, and erythromycin for patients allergic to penicillins. 
However, the increase in not only penicillin-resistant 
Streptococcus pneumoniae but also penicillin-resistant 
Haemophilus influenzae and Moraxella catarrhalis 
make the choice for empirical treatment more difficult. 
The use of fluoroqumolones, especially ciprofloxacin and 
ofloxacin, has limited value, because of their modest activ- 
ity against S. pneumoniae. This continuously evolving 
threat of antimicrobial resistance warrants continuous 
antimicrobial surveillance. 
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Several projects have been directed toward the study 
of respiratory tract infections, especially those caused by 
S. pneumoniae, H. injluenzae, and M. catarrhalis. The 
Surveillance Program of Antibiotic Resistance (SPAR) was 
one of these projects and was implemented in 10 Euro- 
pean countries between December 1994 and April 1995. 
The isolates in that study were tested against six anti- 
biotics at a national level, using local methods.* The 
Alexander Project, also directed at these organisms, 
started in 1992 to study isolates from Europe and the 
United States9 using standard methods. The SENTRY 
antimicrobial surveillance program was established in 
1997 as a global longitudinal program to monitor the fre- 
quency and antimicrobial resistance of clinical isolates 
from blood infections, skin and soft tissue infections, uri- 
nary tract infections, nosocomial pneumonia, and com- 
munity-acquired respiratory tract infections. These isolates 
are referred to key reference centers based in the Nether- 
lands, the United States, and Australia. This report 
describes the isolation frequency and antimicrobial sus- 
ceptibility of S. pneumoniae, H. influenzae, and M. 
catarrhalis obtained from European patients with com- 
munity-acquired respiratory tract infections during the 
first 2 months of the study, starting in April 1997. 
MATERIAL AND METHODS 
The SENTRY Antimicrobial 
Surveillance Program Design 
SENTRY was established to monitor the occurrence and 
antimicrobial susceptibility of both nosocomial and com- 
munity-acquired bacterial pathogens via an international 
network of sentinel hospitals, distributed roughly equally 
by size and location. In this program consecutive bacte- 
rial or fungal isolates, deemed clinically significant by 
local criteria, are forwarded to the regional reference lab- 
oratories to monitor those isolates associated with blood- 
stream infections, pneumonia, skin or soft tissue 
infections, urinary tract infections in hospitalized patients, 
and community-acquired respiratory tract infections due 
to fastidious organisms (S. pneumoniae, H. influenzae, 
and M. cattarhalis). These regional reference laborato- 
ries are located at the University Hospital Utrecht, 
Utrecht, the Netherlands (for Europe), the University of 
Iowa College of Medicine, Iowa City, L4, USA (for North 
and South America), and Women’s and Children’s Hos- 
pital, North Adelaide, Australia (for Australasia). Currently, 
24 hospitals, in 12 European countries are referring iso- 
lates to the European SENTRY reference laboratory 
Referral of Isolates 
Each participating hospital was requested to refer those 
Spneumoniae, H. influenzae, and M. catawbalis isolates 
judged clinically to be the cause of community-acquired 
pneumonia, each calendar month. Only one isolate was 
permitted per patient. Each isolate was speciated at the 
source, according to the routine methodology used at 
the referring hospital, and sent to the Eijkman-Winkler 
Institute for Microbiology, Infectious Diseases, and Inflam- 
mation at the University Hospital Utrecht, using Amies 
charcoal medium transport swabs (Difco, Chicago, IL, 
USA) as the transport medium. Each isolate was accom- 
panied by relevant epidemiologic data, including genus 
and species name, method of identification, date of 
patient’s birth, ward, etc. Upon receipt, isolates were sub- 
cultured onto blood agar to ensure purity Isolate identity 
was confirmed, if necessary. Isolates were snap-frozen in 
brain-heart infusion broth (Oxoid, Chicago, IL, USA) with 
15% glycerol, using liquid nitrogen, and banked at -70°C 
until needed. 
Antimicrobial Agents and Susceptibility Testing 
Minimum inhibitory concentrations (MICs) were deter- 
mined against a range of antibiotics, using a broth 
microdilution method and following standard methods 
defmed by the National Committee for Clinical Laboratory 
Standards (NCCLS, 1998).‘” Cation-adjusted Mueller-Hin- 
ton broth with lysed horse blood (5%) was used as the 
growth medium for Spneumoniae or Haemophilus test 
medium broth for H. infuenzae, throughout the study 
(Dade International, Sacramento, CA, USA). The final 
bacterial inoculum concentration was approximately 
5 X lo5 colony forming units (CFU)/mL. Trays were 
incubated for 20 to 24 hours at 35°C in ambient air, prior 
to determining MIC values. National Committee for Clin- 
ical Laboratory Standards breakpoints were used to inter- 
pret MIC data. Broth microdilution plates were designed 
specifically for the SENTRY study and contained 
extended-range dilutions of the following antibiotics: peni- 
cillin, amoxicillin, amoxicillin-clavulanate, cefotaxime, 
cefepime, ciprofloxacin, ofloxacin, levofloxacin, 
sparfloxacin, gatifloxacin, trovafloxacin, erythromycin, 
clindamycin, azithromycin, clarithromycin, quinopristin- 
dalfopristin, chloramphenicol, rifampin, tetracycline, 
vancomycin, and trimethoprim-sulfamethoxazole. Appro- 
priate quality control was performed using S.pneumo- 
niae ATCC 49619 and H. inJluenzae. 
RESULTS AND DISCUSSION 
Frequency of Isolation 
During the first 10 months of the program, 20 European 
hospitals referred a total of 286 Spneumoniae, 309 H. 
influenzae, and 167 M. catarrhalis isolates to the Euro- 
pean SENTRY reference laboratory. 
Antimicrobial Susceptibility of S. pneumonia 
Of the Spneumoniae isolates tested, 7.0% were highly 
resistant to penicillin and 21.3% showed intermediate 
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Table 1. Antimicrobial Susceptibility and Activity Spectrum (MIC,,J of Antimicrobials Tested against 
S. pneumoniae, H. influenzae, and M. catarrhalis Isolates Implicated in Community-Acquired Respiratory Tract Infections 
PS-s. H-S. PR-S. H. M. 
pneumoniae pneumoniae pneumoniae influenzae catarrhalis 
(n = 205) (n = 61) (n = 20) (n = 309) (n = 167) 
Susceptible Susceptible Susceptible Susceptible Susceptible 
M’C,O,SW fW M’%90 fW M’%LX fW MGW90 (W M’LO (W 
Amoxvcillin <0.06/<0,06 100 0.25/2 68.9 4/8 0 0.5/a NA l/4 NA 
AmoxyciWclavulanate r0.06/10.06 100 0.2512 68.9 418 
Cefotaxime 0.015/0.03 100 0.25/l 86.9 i l l 
Cefepime ~0.06&0.06 100 0.2511 75.4 2/2 
Ciprofloxacin l/l NA l/2 NA i/l 
Levofloxacin l/i 100 l/2 100 l/i 
Sparfloxacin 10.2WO.5 98.5 0.25lO.5 98.4 0.2510.5 
Gatifloxacin* 0.25/0.5 NA 0.2WO.5 NA 0.25/0.5 
Trovafloxacin* 0.2510.5 100 0.25/0.5 100 0.25lO.5 
Etythromycin <0.25/<0.25 90.2 <0.25/>32 67.2 0.5/>32 
Clindamycin 10.06/<0.06 96.1 <0.06/>8 68.9 10.06h6 
Azithromycin <0.12/0.25 94.6 <0.12/>16 68.9 10.12/>16 
Clarithromycin NT NA NT NA NT 
Quinopristin-dalfopristin* 0.511 NA 0.512 NA 0.5/l 
0 0.512 99.4 
30.0 0.015/0.06 100 
5 0.12/0.25 100 
NA ~0.015&0.015 100 
100 <0.05/~0.05 100 
100 10.12K0.12 100 
NA <0.03/<0.03 NA 
100 10.03/10.03 100 
45.0 2/4 - 
65.0 418 NA 
65.0 l/2 99.4 
NA 4/8 90.9 
NA 418 NA 
10.06lO.25 94.6 
0.12/0.5 100 
0.512 100 
~0.012/0.03 100 
<0.5/<0.5 100 
~0.12K0.12 99.4 
~0.03/~0.03 NA 
10.03/~0.03 NA 
$0.25/0.5 
l/2 
~0.12K0.12 
<0.25/<0.25 
0.510.5 
95.2 
31.1 
99.4 
98.2 
NA 
Chloramphenicol <2/<2 97.1 <2/8 77.1 <2/8 55.0 <2K2 97.4 <2K2 99.4 
Rifampin <l/11 99.5 <i&l 100 11/11 95.0 51Kl 97.4 <i/11 98.2 
Tetracycline 12/l 6 85.4 12/>16 55.7 4/>16 45.0 52152 96.4 22152 98.2 
Vancomycin 0.25/0.5 100 0.25/0.5 100 0.2WO.5 100 >16/>16 NA >16/>16 NA 
Trimethoprim-sulfamethoxazole <0.25/i NA 2/4 NA 4/4 - SO.2518 NA <0.03/10.03 NA 
*Investigational drug. 
NA = NO susceptibility breakpoints are available for this drug (NCCLS,l998); NT = not tested; PS = penicillin-susceptible; PI = intermediate penicillin-resistant; 
PR = penicillin-resistant. 
resistance. The percentage of highly resistant isolates was 
somewhat lower than that observed in both the Alexan- 
der Project and SPAR, whereas that of isolates with inter- 
mediate resistance was higher.*,l’ This discrepancy may 
have been caused by the somewhat different distribution 
of centers across Europe. The highly resistant isolates 
were obtained from Spain, Portugal, Greece, and France. 
Isolates with intermediate resistance to penicillin were 
obtained from all participating countries, although most 
were obtained from those countries where highly peni- 
cillin-resistant pneumococci were isolated. The incidence 
of intermediate penicillin-resistant pneumococci was 
below 12% in Utrecht (the Netherlands), Lausanne 
(Switzerland), Freiburg and Dusseldorf (Germany), and 
London (England). These data more or less reflect the 
data presented in the Alexander Project.‘l 
Highly and intermediate penicillin-resistant S. pneu- 
moniae isolates also showed relatively high levels of resis- 
tance to macrolide antibiotics like erythromycin. The 
susceptibility of penicillin-susceptible isolates for erythro- 
mycin was approximately 90%. This relation between resis- 
tance to penicillin and resistance to macrolide antibiotics 
also was noted in the Alexander Project.” Clindamycm 
has been considered for the eradication of community- 
acquired penicillin-resistant S. pneumoniae, although it 
was not active against H. injluenzae or other respiratory 
tract infections. Jones et al investigated cross-resistance 
between erythromycin and clindamycin and showed that 
a substantial number of isolates were resistant only to the 
former antibiotic.12 In this study, the data indicate that the 
total levels of susceptibility to erythromycin and to clin- 
damycin were roughly equal, demonstrating that the so- 
called M-phenotype is not prevalent (Table 1). 
The fluoroquinolones performed rather well against 
all pneumococci, independent from their resistance to 
penicillin. Susceptibility to sparfloxacin was more than 
98% for penicillin-susceptible isolates and those with 
intermediate resistance, whereas all highly resistant iso- 
lates were susceptible. Although no breakpoints have 
been defined for the other quinolones tested, MI&,, 
data suggest that trovafloxacin and the investigational 
drug gatifloxacin performed equally well, but the per- 
formance of ciprofloxacin and levofloxacin was less than 
that of sparfloxacin. These data are comparable for those 
obtained in SPAR for sparfloxacin and ciprofloxacin. The 
data for ciprofloxacin in the Alexander Project indicated 
a somewhat higher level of resistance (MIC,, was 
2 pg/mL).” The role of quinolones in the treatment of 
respiratory tract infections recently was discussed by 
Geddes and Grossman.13 I4 These authors argue that 
quinolones may be beneficial for the treatment of respi- 
ratory tract infections. Data in the present study indicate 
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that at least the newer quinolones may have potential in 
the treatment of these infections. 
The pneumococcal isolates showed good suscepti- 
bility to the investigational drug quinopristin-dalfopristin 
and to older drugs, such as rifampin. All isolates were sus- 
ceptible to vancomycin. 
Antimicrobial Susceptibility of H. influenzae 
Haemophilus infuenzae isolates were generally highly 
susceptible to all antibiotics tested (more than 96% sus- 
ceptibility), although there were a few exceptions (e.g., 
clarithromycin, with 91% susceptibility) (see Table 1). 
Susceptibility to amoxicillin-clavulanate was 99% and to 
cefepime, cefotaxime, and the fluoroquinolones was 
100%. These results are in general agreement with data 
from SPAR and the Alexander Project.8z11 
Antimicrobial Susceptibility of M. catarrbaZis 
All M. catarrhalis isolates were fully susceptible to 
cefepime, cefotaxime, trimethoprim-sulfamethoxazole, 
ciprofloxacin, and levofloxacin (see Table 1). More than 
99% of the isolates were susceptible to sparfloxacin and 
azithromycin. In contrast, susceptibility to penicillin, 
vancomycin, and cliidamycin was poor (S%, 7%, and 31% 
susceptibility, respectively). Results from SPAR and the 
Alexander Project were comparable to present results8~” 
CONCLUSION 
Penicillins used to be first-choice antibiotics for the empir- 
ical treatment of pneumococcal infections. However, the 
emergence of penicillin-resistant Spneumoniae in some 
parts of Europe requires more regional protocols for 
empirical treatment. The newer fluoroquinolones may 
play a role in the empirical treatment of Spneumoniae, 
especially when penicillin resistance is expected. These 
newer fluoroquinolones along with macrolides also may 
play a role in the empirical treatment of H. influenzae 
and M. catarrhalis infections 
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